Research
Epitranscriptomics & Cancer Adaptation : A.David

Activities

Our research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic & translational control.

More..

Zotero public









Cancel


123>>>
56 Items
Title  Creator  Group name  Publishing year 
Regorafenib plus FOLFIRINOX as first-line treatment for patients with RAS-mutant metastatic colorectal cancer (FOLFIRINOX-R trial): a dose-escalation study Adenis et al. EquipeMY 2024-09
Post-surgery sequelae unrelated to disease progression and chemotherapy revealed in follow-up of patients with stage III colon cancer Mirandola et al. EquipeMY 2024-09-19
Tumor Growth Rate Informs Treatment Efficacy in Metastatic Pancreatic Adenocarcinoma: Application of a Growth and Regression Model to Pivotal Trial and Real-World Data Yeh et al. EquipeMY 2023-02-08
Stereotactic MR-Guided Radiotherapy for Liver Metastases: First Results of the Montpellier Prospective Registry Study Bordeau et al. EquipeJPP 2023-02-02
Individual Participant Data Network Meta-Analysis of Neoadjuvant Chemotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Junction Carcinoma Faron et al. EquipeMY 2023-10-01
A straightforward method to quantify circulating mRNAs as biomarkers of colorectal cancer Grosgeorges et al. EquipeMY 2023-02-15
A prospective registry study of stereotactic magnetic resonance guided radiotherapy (MRgRT) for primary liver tumors Bordeau et al. EquipeMY 2023-09-20
[hPG80 and cancer: A new blood biomarker in development for patient monitoring] You et al. EquipeMY 2022-06
The landscape of cancer-associated fibroblasts in colorectal cancer liver metastases Giguelay et al. EquipePM 2022
The desmoplastic growth pattern is associated with second-stage completion and longer survival in 2-stage hepatectomy for colorectal cancer liver metastases Khellaf et al. EquipeMY 2022-09-08
Stereotactic MR-Guided Radiotherapy for Pancreatic Tumors: Dosimetric Benefit of Adaptation and First Clinical Results in a Prospective Registry Study Michalet et al. EquipeMY 2022
Stereotactic MR-Guided Adaptive Radiotherapy for Pancreatic Tumors: Updated Results of the Montpellier Prospective Registry Study Bordeau et al. EquipeJPP 2022-12-20
Perioperative FOLFOX in Patients With Locally Advanced Oesogastric Adenocarcinoma Quesada et al. EquipeMY 2022-01
Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial Conroy et al. EquipeMY 2022-09-01
Chemotherapy (doublet or triplet) plus targeted therapy by RAS status as conversion therapy in colorectal cancer patients with initially unresectable liver-only metastases. The UNICANCER PRODIGE-14 randomised clinical trial Ychou et al. EquipeMY 2022-05
Association of neutrophil extracellular traps with the production of circulating DNA in patients with colorectal cancer Pastor et al. EquipeMY 2022-02-18
Phase II study evaluating the association of gemcitabine, trastuzumab and erlotinib as first-line treatment in patients with metastatic pancreatic adenocarcinoma (GATE 1) Assenat et al. EquipeMY 2021-02-01
No Association of Early-Onset Breast or Ovarian Cancer with Early-Onset Cancer in Relatives in BRCA1 or BRCA2 Mutation Families Imbert-Bouteille et al. EquipePC 2021-07-20
Image-Guided Liver Stereotactic Body Radiotherapy Using VMAT and Real-Time Adaptive Tumor Gating: Evaluation of the Efficacy and Toxicity for Hepatocellular Carcinoma Cantaloube et al. EquipeMY 2021-09-28
CD44v6 Defines a New Population of Circulating Tumor Cells Not Expressing EpCAM Belthier et al. EquipeMY 2021-10-02
[Does the FLOT regimen a new standard of perioperative chemotherapy for localized gastric cancer?] Adenis et al. EquipeMY Jan 21, 2020
Sorafenib Plus Irinotecan Combination in Patients With RAS-mutated Metastatic Colorectal Cancer Refractory To Standard Combined Chemotherapies: A Multicenter, Randomized Phase 2 Trial (NEXIRI-2/PRODIGE 27) Samalin et al. EquipeMY May 15, 2020
Machine Learning-Assisted Evaluation of Circulating DNA Quantitative Analysis for Cancer Screening Tanos et al. EquipeCTCS 2020-09
Guidelines for time-to-event end-point definitions in adjuvant randomised trials for patients with localised colon cancer: Results of the DATECAN initiative Cohen et al. EquipeMY 05/2020
The oncogenic and druggable hPG80 (Progastrin) is overexpressed in multiple cancers and detected in the blood of patients You et al. EquipeMY Dec 23, 2019
123>>>
56 Items


Who are we ?

Located in the Parc Euromédecine, the Institut de Recherche en Cancérologie de Montpellier (U1194) is located on the Val d'Aurelle Campus (ICM, Institut régional du Cancer Montpellier/ Val d'Aurelle).

U1194 Research Centre supported by Inserm, the University of Montpellier and the Institut du Cancer de Montpellier (ICM)

More                                                                                                                 Join us

Contact us

Institut de Recherche en Cancérologie de
Montpellier (U1194) - Campus Val d'Aurelle

208 avenue des Apothicaires
34298 Montpellier cedex 5 FRANCE

 

insermUM1ICM

© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés